Wikipedia

Jane Davies

Jane Carolyn Davies OBE (born 9 November 1963) is a British physician who is Professor of Paediatric Respirology at Imperial College School of Medicine.[1][2][3] She is an Honorary Consultant at the Royal Brompton and Harefield NHS Foundation Trust.

Jane Davies
Born
Jane C. Davies

(1963-11-09) 9 November 1963 (age 61)[citation needed]
Alma materUniversity of Dundee
Royal Brompton Hospital
Scientific career
FieldsCystic fibrosis
Gene therapy[1]
InstitutionsImperial College London
Websiteimperial.ac.uk/people/j.c.davies

Early life and education

edit

Davies studied medicine at the University of Dundee.[4] She graduated in 1987, and began paediatric training in London.[4] She began to work at the Royal Brompton Hospital on cystic fibrosis.[4] She earned her MD[when?][where?] on host-pathogen interactions under the supervision of Andrew Bush and Eric Alton. She looked at the pathogensis of Pseudomonas aeruginosa.[4] She worked at Great Ormond Street Hospital.[5]

Career and research

edit

Davies joined the National Heart and Lung Institute in 1999, where she has specialised in cystic fibrosis.[6] Davies has been involved with the UK CF Gene Therapy Consortium since it was established in 2002.[4] Davies worked on the development of Cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy.[1][7] She led the first trials of CFTR modulators in young children. She conducts bronchoscopic assays and electrophysiological measurements.[4] She was made a Reader in 2009 and a Professor in 2013.[4] Davies investigates cystic fibrosis. She was involved with a major UK trial of gene therapy for cystic fibrosis.[8]

Davies leads the Strategic Research Centre for Pseudomonas Infection in Cystic Fibrosis at Imperial College London, one of few centres supported by the Cystic Fibrosis Trust.[9] The centre looks to identify new ways to detect pseudomonas aeruginosa.[10][11] Davies is part of the European CF Society Clinical Trials Network.[4][12][13] She was involved in the design of the clinical trial, as well as validation of outcome measures.[14][15] She works on the use of nasal potential difference to diagnose atypical cystic fibrosis.[4][16] She was awarded a £2.8 million research grant from the Wellcome Trust to optimise the lentiviral vector for gene therapy.

In 2020 she won the Senior Investigator award from the National Institute for Health Research (NIHR).[17]

Publications

edit

Davies publications[1][2][3] include:

  • Davies, Jane (2006). "Current and Novel Antimicrobial Approaches". In Bush, A. (ed.). Cystic Fibrosis in the 21st Century. London: S. Karger. ISBN 9783318012408. OCLC 728412484.
  • Greisenbach, U.; Alton, E.W.F.W.; Davies, J.C. (2006). "CF Modifier Genes". In Bush, Andrew (ed.). Cystic Fibrosis in the 21st Century. Basel: Karger. ISBN 1423796802. OCLC 71126311.
  • 2011 An Atlas of Investigation and Management. Paediatric Respiratory Disease: Vol 1 Airways & Infection[ISBN missing]
  • 2011 An Atlas of Investigation and Management. Paediatric Respiratory Disease: Vol 2 Parenchymal Disease[ISBN missing]
  • Alton, Eric W; Davies, Jane C; Griesenbach, Uta (2013). Current & Emerging Pharmaceutical Treatments for Cystic Fibrosis Lung Disease. pp. 2–4. doi:10.2217/ebo.13.170. ISBN 978-1-78084-096-3.

References

edit
  1. ^ a b c d Jane Davies publications indexed by Google Scholar  
  2. ^ a b Jane Davies publications indexed by the Scopus bibliographic database. (subscription required)
  3. ^ a b Jane Davies publications from Europe PubMed Central
  4. ^ a b c d e f g h i "Home - Professor Jane Davies". imperial.ac.uk. Retrieved 2019-02-25.
  5. ^ Yoxall, Edward. "Tackling Cystic Fibrosis". felixonline.co.uk. Retrieved 2019-02-26.
  6. ^ Bush, Andrew; Alton, Eric W. F. W.; Davies, Jane C. (2007). "Cystic fibrosis". BMJ. 335 (7632): 1255–1259. doi:10.1136/bmj.39391.713229.AD. ISSN 0959-8138. PMC 2137053. PMID 18079549.
  7. ^ Ramsey, Bonnie W.; Davies, Jane; McElvaney, N. Gerard; Tullis, Elizabeth; Bell, Scott C.; Dřevínek, Pavel; Griese, Matthias; McKone, Edward F.; Wainwright, Claire E.; Konstan, Michael W.; Moss, Richard; Ratjen, Felix; Sermet-Gaudelus, Isabelle; Rowe, Steven M.; Dong, Qunming; Rodriguez, Sally; Yen, Karl; Ordoñez, Claudia; Elborn, J. Stuart (2011). "A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation". New England Journal of Medicine. 365 (18): 1663–1672. doi:10.1056/NEJMoa1105185. ISSN 0028-4793. PMC 3230303. PMID 22047557.
  8. ^ "Prof Jane Davies - CF gene therapy | Interviews | Naked Scientists". thenakedscientists.com. 6 July 2014. Retrieved 2019-02-25.
  9. ^ "Strategic Research Centre for Pseudomonas Infection in Cystic Fibrosis". Imperial College London. Retrieved 2019-02-25.
  10. ^ "Strategic Research Centre: Personalised approach to Pseudomonas aeruginosa (PAPA)". cysticfibrosis.org.uk. Retrieved 2019-02-25.
  11. ^ Imperial College London (2017-07-28), Detecting and treating infection in cystic fibrosis, retrieved 2019-02-25
  12. ^ "Prof Jane Davies". Paediatric Respiratory Conference. Retrieved 2019-02-25.
  13. ^ "cfcourse". cfcourse-online.co.uk. Retrieved 2019-02-25.
  14. ^ "Just Gene Therapy: About us - Imperial College London". justgenetherapy.org. Retrieved 2019-02-25.
  15. ^ "Dr Jane Davies MB Chb". Enterprise Therapeutics. Retrieved 2019-02-25.
  16. ^ "Strategic Research Centre: Pseudomonas". cysticfibrosis.org.uk. Retrieved 2019-02-25.
  17. ^ "Professor Jane Davies recognised with leadership award | Royal Brompton & Harefield hospitals". www.rbht.nhs.uk. Retrieved 2022-02-09.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Jane_Davies&oldid=1258437389"